Read this company snapshot
Daily valuation snapshot
NeuroSense Therapeutics Ltd. Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $3.66
- Market capitalization (USD)
- $6,942,661.32
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research NRSN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research NRSN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing NRSN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $3.66 |
| Market capitalization (USD) | $6,942,661.32 |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read NRSN's valuation metrics
Company size
NeuroSense Therapeutics Ltd. Ordinary Shares's recorded market capitalization is $6,942,661.32. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research NeuroSense Therapeutics Ltd. Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about NRSN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow NRSN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.